Submitted:
21 May 2026
Posted:
22 May 2026
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Design and Population
- Age between 3 and 18 years
- Availability of food-specific IgG testing
- Availability of abdominal ultrasound examination
- Availability of intestinal inflammatory/permeability biomarkers
- Presence of recurrent gastrointestinal symptoms for at least 3 months (symptomatic groups)
- Confirmed celiac disease
- Inflammatory bowel disease diagnosed by endoscopy and histopathology
- Known IgE-mediated food allergy
- Severe chronic systemic disease (oncological, metabolic, or severe autoimmune disorders)
- Recent systemic corticosteroid or immunosuppressive therapy
- Acute gastrointestinal infection at presentation
2.2. Food-Specific IgG Antibody Assessment
- Class 0 (≤15 U/mL): no detectable reactivity
- Class 1 (15–25 U/mL): low reactivity
- Class 2 (25–50 U/mL): moderate reactivity
- Class 3 (>50 U/mL): high-intensity reactivity
- gluten-containing cereals
- dairy proteins
- mixed gluten–dairy reactivity
2.3. Intestinal Inflammatory and Permeability Biomarkers
- Fecal calprotectin, as a marker of mucosal inflammation
- Zonulin, as an indicator of intestinal epithelial permeability
- Fecal histamine, reflecting mast-cell-related mucosal activation
- Microbiological stool testing, including assessment for Dientamoeba fragilis
2.4. Abdominal Ultrasound Assessment
- low-frequency convex transducer (1–6 MHz) for deep abdominal evaluation
- high-frequency linear transducer (5–12 MHz) for detailed assessment of bowel wall layers and mesenteric lymph nodes
- Bowel wall thickening/edema: >3 mm, Mesenteric lymphadenopathy: lymph nodes >8 mm short-axis diameter. All ultrasound examinations were performed by a single experienced pediatric physician with certified ultrasonography competence, ensuring methodological consistency and minimizing inter-observer variability.
2.5. Clinical Symptom Assessment
- 0 = absent
- 1 = mild
- 2 = moderate
- 3 = severe
2.6. Statistical Analysis
3. Results
3.1. Demographic, Clinical, and Biomarker Characteristics of the Study Population
3.2. Ultrasound Findings and Their Relationship with Immune Activation
3.3. Correlation Analysis Between Immune Markers, Inflammatory Biomarkers, and Ultrasound Findings
3.4. Multivariable Logistic Regression Analysis
3.5. Receiver Operating Characteristic (ROC) Analysis
4. Discussion
4.1. Integrated Immune–Gut Perspective and Definition of a Novel Pediatric Inflammatory Phenotype
4.2. Clinical Significance of Food-Specific IgG Reactivity
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Korterink, J.J.; Diederen, K.; Benninga, M.A.; Tabbers, M.M. Epidemiology of Pediatric Functional Abdominal Pain Disorders: A Meta-Analysis. PLOS ONE 2015, 10, e0126982–e0126982. [CrossRef]
- Robin, S.G.; Keller, C.; Zwiener, R.; Hyman, P.E.; Nurko, S.; Saps, M.; Di Lorenzo, C.; Shulman, R.J.; Hyams, J.S.; Palsson, O.; et al. Prevalence of Pediatric Functional Gastrointestinal Disorders Utilizing the Rome IV Criteria. J. Pediatr. 2018, 195, 134–139. [CrossRef]
- Hyams, J.S.; Di Lorenzo, C.; Saps, M.; Shulman, R.J.; Staiano, A.; van Tilburg, M. Childhood Functional Gastrointestinal Disorders: Child/Adolescent. Gastroenterology 2016, 150, 1456–1468.e2. [CrossRef]
- Groetch, M.; Venter, C.; Meyer, R. Clinical Presentation and Nutrition Management of Non-IgE-Mediated Food Allergy in Children. Clin. Exp. Allergy 2025. [CrossRef]
- Chehade, M.; Jones, S.M.; Pesek, R.D.; Burks, A.W.; Vickery, B.P.; Wood, R.A.; Leung, D.Y.; Furuta, G.T.; Fleischer, D.M.; Henning, A.K.; et al. Phenotypic Characterization of Eosinophilic Esophagitis in a Large Multicenter Patient Population from the Consortium for Food Allergy Research. J. Allergy Clin. Immunol. Pr. 2018, 6, 1534–1544.e5. [CrossRef]
- Santos, A.F.; Riggioni, C.; Agache, I.; Akdis, C.A.; Akdis, M.; Alvarez-Perea, A.; Alvaro-Lozano, M.; Ballmer-Weber, B.; Barni, S.; Beyer, K.; et al. EAACI guidelines on the diagnosis of IgE-mediated food allergy. Allergy 2023, 78, 3057–3076. [CrossRef]
- Gocki, J.; Bartuzi, Z. Role of immunoglobulin G antibodies in diagnosis of food allergy. Adv. Dermatol. Allergol. 2016, 4, 253–256. [CrossRef]
- Zeng, Q.; Dong, S.-Y.; Wu, L.-X.; Li, H.; Sun, Z.-J.; Li, J.-B.; Jiang, H.-X.; Chen, Z.-H.; Wang, Q.-B.; Chen, W.-W. Variable Food-Specific IgG Antibody Levels in Healthy and Symptomatic Chinese Adults. PLOS ONE 2013, 8, e53612. [CrossRef]
- Garmendia, J.V.; De Sanctis, C.V.; Hajdúch, M.; De Sanctis, J.B. Microbiota and Recurrent Pregnancy Loss (RPL); More than a Simple Connection. Microorganisms 2024, 12, 1641. [CrossRef]
- McGowan, E.C.; Medernach, J.; Keshavarz, B.; Workman, L.J.; Li, R.; Barnes, B.H.; Sauer, B.; Wilson, J.M.; Platts-Mills, T.A.E. Food antigen consumption and disease activity affect food-specific IgG4 levels in patients with eosinophilic esophagitis (EoE). Clin. Exp. Allergy 2022, 53, 307–315. [CrossRef]
- Xiao, N.; Liu, F.; Zhou, G.; Sun, M.; Ai, F.; Liu, Z. Food-specific IgGs Are Highly Increased in the Sera of Patients with Inflammatory Bowel Disease and Are Clinically Relevant to the Pathogenesis. Intern. Med. 2018, 57, 2787–2798. [CrossRef]
- Yang, B.; Yu, H.; Yao, W.; Diao, R.; Li, B.; Wang, Y.; Li, T.; Ge, L.; Hu, Y.; Wang, H. Food-specific IgG4-guided diet elimination improves allergy symptoms in children. Front. Immunol. 2024, 15, 1281741. [CrossRef]
- Peruhova, M.; Mihova, A.; Altankova, I.; Velikova, T. Specific Immunoglobulin E and G to Common Food Antigens and Increased Serum Zonulin in IBS Patients: A Single-Center Bulgarian Study. Antibodies 2022, 11, 23. [CrossRef]
- Cappelletti, M.; Tognon, E.; Vona, L.; Basello, K.; Costanzi, A.; Speciani, M.C.; Speciani, A.F. Food-specific serum IgG and symptom reduction with a personalized, unrestricted-calorie diet of six weeks in Irritable Bowel Syndrome (IBS). Nutr. Metab. 2020, 17, 1–6. [CrossRef]
- Guo, H.; Jiang, T.; Wang, J.; Chang, Y.; Guo, H.; Zhang, W. The Value of Eliminating Foods According to Food-Specific Immunoglobulin G Antibodies in Irritable Bowel Syndrome with Diarrhoea. J. Int. Med Res. 2012, 40, 204–210. [CrossRef]
- Ostrowska, L.; Wasiluk, D.; Lieners, C.F.J.; Gałęcka, M.; Bartnicka, A.; Tveiten, D. Igg Food Antibody Guided Elimination-Rotation Diet Was More Effective than FODMAP Diet and Control Diet in the Treatment of Women with Mixed IBS—Results from an Open Label Study. J. Clin. Med. 2021, 10, 4317. [CrossRef]
- Laura-Mihaela, I.; Pavelescu, C.; Denisa Maria, C.; Oros, M.; Jugulete, G.; Alina, S.; Mihaela, D.; Diaconescu, S. Food-Specific IgG Reactivity and Intestinal Ultrasound Abnormalities in Symptomatic Children: A Multimodal Assessment of Low-Grade Immune-Mediated Gut Inflammation. Preprints 2026, 2026041180. [CrossRef]
- Zar, S.; Mincher, L.; Benson, M.J.; Kumar, D. Food-specific IgG4 antibody-guided exclusion diet improves symptoms and rectal compliance in irritable bowel syndrome. Scand. J. Gastroenterol. 2005, 40, 800–807. [CrossRef]
- Patt, Y.S.; Lahat, A.; David, P.; Patt, C.; Eyade, R.; Sharif, K. Unraveling the Immunopathological Landscape of Celiac Disease: A Comprehensive Review. Int. J. Mol. Sci. 2023, 24, 15482. [CrossRef]
- Tordesillas, L.; Berin, M.C. Mechanisms of Oral Tolerance. Clin. Rev. Allergy Immunol. 2018, 55, 107–117. [CrossRef]
- Suurmond, J.; Diamond, B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J. Clin. Investig. 2015, 125, 2194–2202. [CrossRef]
- Wang, Y.; Mo, Y.; Sun, Y.; Li, J.; An, Y.; Feng, N.; Liu, Y. Intestinal nanoparticle delivery and cellular response: a review of the bidirectional nanoparticle-cell interplay in mucosa based on physiochemical properties. J. Nanobiotechnology 2024, 22, 1–23. [CrossRef]
- Schoultz, I.; Keita, Å.V. Cellular and Molecular Therapeutic Targets in Inflammatory Bowel Disease—Focusing on Intestinal Barrier Function. Cells 2019, 8. [CrossRef]
- König, J.; Wells, J.; Cani, P.D.; García-Ródenas, C.L.; Macdonald, T.; Mercenier, A.; Whyte, J.; Troost, F.; Brummer, R.-J. Human Intestinal Barrier Function in Health and Disease. Clin. Transl. Gastroenterol. 2016, 7, e196. [CrossRef]
- Seethaler, B.; Basrai, M.; Neyrinck, A.M.; Nazare, J.-A.; Walter, J.; Delzenne, N.M.; Bischoff, S.C. Biomarkers for assessment of intestinal permeability in clinical practice. Am. J. Physiol. Liver Physiol. 2021, 321, G11–G17. [CrossRef]
- Zengil, S.; Laloğlu, E. Evaluation of serum zonulin and occludin levels in obsessive-compulsive disorder and the effect of major depressive disorder comorbidity. Front. Psychiatry 2024, 15, 1395235. [CrossRef]
- Fasano, A.; Not, T.; Wang, W.; Uzzau, S.; Berti, I.; Tommasini, A.; Goldblum, S.E. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet 2000, 355, 1518–1519. [CrossRef]
- Sturgeon, C.; Fasano, A. Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases. Tissue Barriers 2016, 4, e1251384. [CrossRef]
- Camilleri, M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut 2019, 68, 1516–1526. [CrossRef]
- Hoshiko, H.; Feskens, E.J.M.; Oosterink, E.; Ariens, R.M.C.; Mes, J.J.; de Wit, N.J.W. Identification of leaky gut-related markers as indicators of metabolic health in Dutch adults: The Nutrition Questionnaires plus (NQplus) study. PLOS ONE 2021, 16, e0252936. [CrossRef]
- Xiao, Y.-T.; Yan, W.-H.; Cao, Y.; Yan, J.-K.; Cai, W. Neutralization of IL-6 and TNF-α ameliorates intestinal permeability in DSS-induced colitis. Cytokine 2016, 83, 189–192. [CrossRef]
- Fukao, S.; Haniuda, K.; Tamaki, H.; Kitamura, D. Protein kinase Cδ is essential for the IgG response against T-cell-independent type 2 antigens and commensal bacteria. eLife 2021, 10. [CrossRef]
- Vita, A.A.; Zwickey, H.; Bradley, R. Associations between food-specific IgG antibodies and intestinal permeability biomarkers. Front. Nutr. 2022, 9, 962093. [CrossRef]
- Pimentel, M.; Lembo, A. Microbiome and Its Role in Irritable Bowel Syndrome. Dig. Dis. Sci. 2020, 65, 829–839. [CrossRef]
- Mohammad, S.; Thiemermann, C. Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions. Front. Immunol. 2021, 11. [CrossRef]
- McDonald, C.M.; Manji, K.P.; Gosselin, K.; Tran, H.; Liu, E.; Kisenge, R.; Aboud, S.; Fawzi, W.W.; Gewirtz, A.T.; Duggan, C.P. Elevations in serum anti-flagellin and anti-LPS Igs are related to growth faltering in young Tanzanian children. Am. J. Clin. Nutr. 2016, 103, 1548–1554. [CrossRef]
- Morales, W.; Rezaie, A.; Barlow, G.; Pimentel, M. Second-Generation Biomarker Testing for Irritable Bowel Syndrome Using Plasma Anti-CdtB and Anti-Vinculin Levels. Dig. Dis. Sci. 2019, 64, 3115–3121. [CrossRef]
- Rezaie, A.; Park, S.C.; Morales, W.; Marsh, E.; Lembo, A.; Kim, J.H.; Weitsman, S.; Chua, K.S.; Barlow, G.M.; Pimentel, M. Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome. Dig. Dis. Sci. 2017, 62, 1480–1485. [CrossRef]
- Pokkunuri, V.; Pimentel, M.; Morales, W.; Jee, S.-R.; Alpern, J.; Weitsman, S.; Marsh, Z.; Low, K.; Hwang, L.; Khoshini, R.; et al. Role of Cytolethal Distending Toxin in Altered Stool Form and Bowel Phenotypes in a Rat Model of Post-infectious Irritable Bowel Syndrome. J. Neurogastroenterol. Motil. 2012, 18, 434–442. [CrossRef]
- Pons, B.J.; Vignard, J.; Mirey, G. Cytolethal Distending Toxin Subunit B: A Review of Structure–Function Relationship. Toxins 2019, 11, 595. [CrossRef]
- Vojdani, A.; Vojdani, E.; Kharrazian, D. Fluctuation of zonulin levels in bloodvsstability of antibodies. World J. Gastroenterol. 2017, 23, 5669–5679. [CrossRef]
- Vojdani, A.; Vojdani, E.; Herbert, M.; Kharrazian, D. Correlation between Antibodies to Bacterial Lipopolysaccharides and Barrier Proteins in Sera Positive for ASCA and ANCA. Int. J. Mol. Sci. 2020, 21, 1381. [CrossRef]
- Cole, C.R.; Frem, J.C.; Schmotzer, B.; Gewirtz, A.T.; Meddings, J.B.; Gold, B.D.; Ziegler, T.R. The Rate of Bloodstream Infection Is High in Infants with Short Bowel Syndrome: Relationship with Small Bowel Bacterial Overgrowth, Enteral Feeding, and Inflammatory and Immune Responses. J. Pediatr. 2010, 156, 941–947.e1. [CrossRef]
- Pei, R.; DiMarco, D.M.; Putt, K.K.; Martin, D.A.; Gu, Q.; Chitchumroonchokchai, C.; White, H.M.; Scarlett, C.O.; Bruno, R.S.; Bolling, B.W. Low-fat yogurt consumption reduces biomarkers of chronic inflammation and inhibits markers of endotoxin exposure in healthy premenopausal women: a randomised controlled trial. Br. J. Nutr. 2017, 118, 1043–1051. [CrossRef]
- Ott, B.; Skurk, T.; Lagkouvardos, L.; Fischer, S.; Büttner, J.; Lichtenegger, M.; Clavel, T.; Lechner, A.; Rychlik, M.; Haller, D.; et al. Short-Term Overfeeding with Dairy Cream Does Not Modify Gut Permeability, the Fecal Microbiota, or Glucose Metabolism in Young Healthy Men. J. Nutr. 2018, 148, 77–85. [CrossRef]
- Chen, M.-X.; Chen, Y.; Fu, R.; Mao, G.-Q.; Liu, S.-Y.; Shen, T.-B. Rab5a Promotes Cytolethal Distending Toxin B-Induced Cytotoxicity and Inflammation. Infect. Immun. 2020, 88. [CrossRef]
- Varon, C.; Mocan, I.; Mihi, B.; Péré-Védrenne, C.; Aboubacar, A.; Moraté, C.; Oleastro, M.; Doignon, F.; Laharie, D.; Mégraud, F.; et al. Helicobacter pullorum Cytolethal Distending Toxin Targets Vinculin and Cortactin and Triggers Formation of Lamellipodia in Intestinal Epithelial Cells. J. Infect. Dis. 2014, 209, 588–599. [CrossRef]
- Madhavan, R.; Porkodi, R.; Rajendran, C.P.; Chandrasekaran, A.N.; Umadevi, K.R.; Alamelu, R. IgM, IgG, and IgA response to enterobacteria in patients with ankylosing spondylitis in southern India.. Ann. New York Acad. Sci. 2006, 958, 408–411. [CrossRef]
- Burk, C.M.; Shreffler, W.G. Triggers for eosinophilic esophagitis (EoE): The intersection of food allergy and EoE. J. Allergy Clin. Immunol. 2024, 153, 1500–1509. [CrossRef]
- American Academy of Allergy, Asthma & Immunology. The myth of IgG food panel testing. Available online: https://www.aaaai.org/tools-for-the-public/conditions-library/allergies/igg-food-test (accessed on 23 February 2026).
- Harris, P.A.; Taylor, R.; Thielke, R.; Payne, J.; Gonzalez, N.; Conde, J.G. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 2009, 42, 377–381. [CrossRef]
- Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN; REDCap Consortium. The REDCap consortium: Building an international community of software platform partners. J. Biomed. Inform. 2019, 95, 103208. [CrossRef]
- Bays, J.L.; DeMali, K.A. Vinculin in cell–cell and cell–matrix adhesions. Cell. Mol. Life Sci. 2017, 74, 2999–3009. [CrossRef]








| Variable | IAIP (n=196) | Symptomatic (n=146) | Controls (n=210) | p-value |
| Age (years), mean ± SD | 9.8 ± 4.1 | 9.3 ± 4.0 | 9.5 ± 3.9 | NS |
| Male sex (%) | 56% | 56% | 55% | NS |
| Abdominal pain (%) | 91% | 74% | 8% | <0.01 |
| Bloating (%) | 82% | 61% | 5% | <0.005 |
| Altered bowel habits (%) | 76% | 49% | 4% | <0.01 |
| Nausea/Vomiting (%) | 48% | 31% | 3% | <0.01 |
| Fatigue (%) | 58% | 29% | 3% | <0.0001 |
| Dermatological symptoms (%) | 37% | 18% | 2% | <0.0001 |
| IgG ≥5 foods (%) | 88% | 76% | 24% | <0.0001 |
| IgG ≥10 foods (%) | 65% | 42% | 8% | <0.01 |
| Dairy IgG reactivity (%) | 78% | 62% | 18% | <0.0001 |
| Gluten IgG reactivity (%) | 70% | 53% | 15% | <0.01 |
| Mixed dairy–gluten reactivity (%) | 58% | 38% | 7% | <0.0001 |
| Elevated calprotectin (%) | 74% | 31% | 2% | <0.0001 |
| Elevated zonulin (%) | 69% | 28% | 2% | <0.0001 |
| Elevated fecal histamine (%) | 54% | 19% | 1% | <0.0001 |
| Dientamoeba fragilis positivity (%) | 28% | 9% | 1% | <0.0001 |
| Ultrasound Finding | IAIP (n=196) | Symptomatic (n=146) | Controls (n=210) | p-value |
| Bowel wall edema/thickening >3 mm (%) | 69% | 31% | 1% | <0.0001 |
| Terminal Ileum involvement (%) | 58% | 24% | 0% | <0.01 |
| Right colon involvement (%) | 51% | 18% | 0% | <0.01 |
| Mesenteric lymphadenopathy >8 mm (%) | 61% | 15% | 1% | <0.0001 |
| Doppler hypervascularization (%) | 32% | 8% | 0% | <0.0001 |
| Variables Compared | Correlation (r) | p-value | Interpretation |
| IgG burden vs bowel wall thickness | 0.48 | <0.0001 | Moderate positive correlation |
| Calprotectin vs bowel wall thickness | 0.62 | <0.0001 | Strong positive correlation |
| Zonulin vs IgG burden | 0.55 | <0.0001 | Moderate–strong correlation |
| Zonulin vs calprotectin | 0.51 | <0.0001 | Moderate positive correlation |
| Histamine vs abdominal pain severity | 0.39 | <0.001 | Moderate correlation |
| D. fragilis positivity vs calprotectin | 0.31 | <0.01 | Weak–moderate correlation |
| Mesenteric adenopathy vs calprotectin | 0.50 | <0.0001 | Moderate positive correlation |
| Predictor | Adjusted OR | 95% CI | p-value |
| IgG ≥10 foods | 4.9 | 2.9–8.6 | <0.0001 |
| Mixed dairy–gluten IgG reactivity | 5.4 | 3.1–9.3 | <0.0001 |
| Elevated calprotectin | 7.8 | 4.5–13.4 | <0.0001 |
| Elevated zonulin | 6.5 | 3.8–11.1 | <0.0001 |
| Elevated fecal histamine | 3.2 | 1.7–6.0 | 0.001 |
| D. fragilis positivity | 3.7 | 1.8–7.4 | <0.001 |
| Model | AUC (95% CI) | Sensitivity | Specificity |
| IgG reactivity alone | 0.79 | 76% | 69% |
| Ultrasound alone | 0.83 | 68% | 91% |
| Calprotectin alone | 0.86 | 81% | 88% |
| IgG + ultrasound | 0.89 | 74% | 89% |
| Full multimodal model | 0.94 | 88% | 92% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.